These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 16365747

  • 1. Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period.
    Haas PS, Bauchmüller K, Kühnemund A, Finke J, Ihorst G, Engelhardt M.
    Ann Hematol; 2006 Mar; 85(3):191-3. PubMed ID: 16365747
    [No Abstract] [Full Text] [Related]

  • 2. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH, Korean Multiple Myeloma Working Party.
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
    Kroschinsky F, Hölig K, Platzbecker U, Poppe-Thiede K, Ordemann R, Blechschmidt M, Oelschlaegel U, Schaich M, Hänel M, Bornhäuser M, Ehninger G.
    Transfusion; 2006 Aug; 46(8):1417-23. PubMed ID: 16934080
    [Abstract] [Full Text] [Related]

  • 4. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
    Ergene U, Cağirgan S, Pehlivan M, Yilmaz M, Tombuloğlu M.
    Transfus Apher Sci; 2007 Feb; 36(1):23-9. PubMed ID: 17292672
    [Abstract] [Full Text] [Related]

  • 5. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P.
    Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
    [Abstract] [Full Text] [Related]

  • 6. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan.
    Vela-Ojeda J, García-Ruiz-Esparza MA, Padilla-González Y, Gómez-Almaguer D, Gutiérrez-Aguirre CH, Gómez-Rangel D, Morales-Toquero A, Ruiz-Delgado GJ, Delgado-Lamas JL, Ruiz-Argüelles GJ.
    Ann Hematol; 2007 Apr; 86(4):277-82. PubMed ID: 17262193
    [Abstract] [Full Text] [Related]

  • 7. Trial of amifostine in autologous stem cell transplant.
    Sastry P, Bhagwat R, Biswas G, Khadwal A, Narayanan P, Bakshi A, Parikh P.
    Bone Marrow Transplant; 2006 Jan; 37(1):117-8. PubMed ID: 16273114
    [No Abstract] [Full Text] [Related]

  • 8. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.
    Benson DM, Elder PJ, Lin TS, Blum W, Penza S, Avalos B, Copelan E, Farag SS.
    Leuk Res; 2007 Aug; 31(8):1069-75. PubMed ID: 17070906
    [Abstract] [Full Text] [Related]

  • 9. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma.
    Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J.
    Bone Marrow Transplant; 2002 Nov; 30(10):673-9. PubMed ID: 12420206
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
    Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T.
    Bone Marrow Transplant; 2006 Sep; 38(6):417-20. PubMed ID: 16951691
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Health-related quality of life in multiple myeloma survivors treated with high dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation: a retrospective analysis.
    Slovacek L, Slovackova B, Pavlik V, Hrstka Z, Macingova Z, Jebavy L, Horacek JM.
    Neoplasma; 2008 Sep; 55(4):350-5. PubMed ID: 18505348
    [Abstract] [Full Text] [Related]

  • 18. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
    O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, Naresh K, Lampert I, Samson D, Narat S, Kanfer E, Olavarria E, Apperley JF, Rahemtulla A.
    Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.